Sandra and Edward Meyer Cancer Center

Two Weill Cornell Medicine faculty members, Dr. David Lyden and Dr. Harel Weinstein have been elected fellows of the American Association for the Advancement of Science (AAAS).

A protein that prepares DNA for replication also prevents the replication process from running out of control, according to a new study by Weill Cornell Medicine researchers.

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells.

A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack.

A new method can illuminate the identities and activities of cells throughout an organ or a tumor at unprecedented resolution.

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells.

An experimental therapy showed promise as treatment for an aggressively spreading type of colorectal cancer in preclinical models.

Weill Cornell Medicine has been awarded a five-year, $8.1 million grant from the National Cancer Institute of the National Institutes of Health to investigate the effects of the immune response in irradiated rectal cancer.

Changes in a single gene open the door for harmful gut bacteria to set off the inflammation that drives Crohn’s disease.

A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers.

Endothelial cells—the cells that line blood vessels—grown alongside leukemia cells become corrupted and rescue the cancer cells from many chemotherapy drugs, a study by Weill Cornell Medicine investigators found.

A common, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce.

Weill Cornell Medicine has been awarded a $1 million, three-year grant from the Department of Defense’s Kidney Cancer Research Program to fund research on the role of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a form of kidney cancer.

Dr. Jedd Wolchok, an internationally acclaimed medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment, has been recruited as the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, effective Sept. 12.

Dr. Steven Josefowicz, an assistant professor in the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine, has won a 2022 Investigators in the Pathogenesis of Infectious Disease (PATH) award from the Burroughs Wellcome Fund.

A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment.

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.

Tumors can force neighboring cells into supporting cancer growth by releasing lactate into their local environment, according to researchers at Weill Cornell Medicine.

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why.